|
CDV3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.19320142444712E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.76110270600338E-11 |
| Normal-vs-Stage2 |
4.299200E-01 |
| Normal-vs-Stage3 |
7.43227701605065E-12 |
| Normal-vs-Stage4 |
4.33131308597012E-12 |
| Stage1-vs-Stage2 |
6.145500E-02 |
| Stage1-vs-Stage3 |
2.592000E-01 |
| Stage1-vs-Stage4 |
7.648100E-02 |
| Stage2-vs-Stage3 |
2.952400E-02 |
| Stage2-vs-Stage4 |
1.790110E-02 |
| Stage3-vs-Stage4 |
5.582000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.32667268468867E-15 |
| Normal-vs-AfricanAmerican |
1.81334999999061E-05 |
| Normal-vs-Asian |
1.986880E-04 |
| Caucasian-vs-AfricanAmerican |
3.830200E-01 |
| Caucasian-vs-Asian |
5.095200E-01 |
| AfricanAmerican-vs-Asian |
9.302000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.35669253609194E-13 |
| Normal-vs-Female |
1.5169000500137E-09 |
| Male-vs-Female |
1.565600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.26870003391844E-09 |
| Normal-vs-Age(41-60Yrs) |
1.81159531820185E-11 |
| Normal-vs-Age(61-80Yrs) |
3.437800E-04 |
| Normal-vs-Age(81-100Yrs) |
6.338900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.033400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.347800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.307000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.964200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.085200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.268200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.689900E-02 |
| Classical-VS-Follicular |
4.555500E-03 |
| Classical-VS-Other |
4.516600E-01 |
| Classical-VS-Normal |
1.62503344114384E-12 |
| Tall-VS-Follicular |
4.560800E-04 |
| Tall-VS-Other |
9.302200E-01 |
| Tall-VS-Normal |
2.39586128714109E-13 |
| Follicular-VS-Other |
3.282000E-02 |
| Follicular-VS-Normal |
7.888200E-02 |
| Other-VS-Normal |
1.437840E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.51430001871233E-09 |
| Normal-vs-N1 |
1.14352971536391E-14 |
| N0-vs-N1 |
2.882200E-03 |
|
|
